Last reviewed · How we verify
No basiliximab
At a glance
| Generic name | No basiliximab |
|---|---|
| Sponsor | Asan Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL (PHASE2, PHASE3)
- Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation (PHASE2)
- Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft (PHASE4)
- Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen (PHASE4)
- Standard Induction With Basiliximab Versus No-Induction in Low Immunological Risk Kidney Transplant Recipients (PHASE4)
- Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation (PHASE4)
- Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen (PHASE2)
- Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- No basiliximab CI brief — competitive landscape report
- No basiliximab updates RSS · CI watch RSS
- Asan Medical Center portfolio CI